SK Bioscience, Colombia Partner for Local Varicella Vaccine Production
SK bioscience, a leading South Korean biopharmaceutical company, has forged a significant partnership with the Colombian government to facilitate the local production of its varicella (chickenpox) vaccine, SKYVaricella. The agreement, finalized through a technology transfer and manufacturing deal, marks a crucial step in strengthening Colombia’s domestic vaccine manufacturing capabilities.
The collaboration will enable Colombia to produce SKYVaricella within its borders, reducing reliance on imports and potentially improving access to the vaccine for its population. Details regarding the specifics of the technology transfer, production scale, and timelines were not immediately released, but the agreement signals a commitment from both parties to bolster public health infrastructure in Colombia.
SKYVaricella is SK bioscience’s chickenpox vaccine, already approved and marketed in several countries. The company has been actively pursuing partnerships to expand its global reach and contribute to vaccine self-sufficiency in various regions. Colombia's decision to partner with SK bioscience demonstrates a strategic effort to enhance its national health security by developing local manufacturing capacity for essential vaccines. The agreement represents a significant investment in Colombia’s biotechnology sector and aligns with broader global efforts to promote vaccine equity and resilience against future health crises.
